OK11 Stock Overview
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
OKYO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.00 |
| 52 Week High | US$1.47 |
| 52 Week Low | US$0.76 |
| Beta | -3.37 |
| 1 Month Change | 4.71% |
| 3 Month Change | 3.63% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| OK11 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.6% | -12.3% | -0.6% |
| 1Y | n/a | -15.3% | 14.8% |
Return vs Industry: Insufficient data to determine how OK11 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how OK11 performed against the German Market.
Price Volatility
| OK11 volatility | |
|---|---|
| OK11 Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: OK11's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: OK11's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 3 | Gary Jacob | okyopharma.com |
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain.
OKYO Pharma Limited Fundamentals Summary
| OK11 fundamental statistics | |
|---|---|
| Market cap | €36.17m |
| Earnings (TTM) | -€10.22m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs OK11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OK11 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$4.49m |
| Gross Profit | -US$4.49m |
| Other Expenses | US$6.19m |
| Earnings | -US$10.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -0.03% |
How did OK11 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 23:34 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OKYO Pharma Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Ashok Kumar | ThinkEquity LLC |